%20by%20%E2%80%9EZoish%E2%80%9D%2C%20licensed%20under%20%E2%80%9ECC0%201.0%E2%80%9D%20(https%3A%2F%2Fcreativecommons.org%2Fpublicdomain%2Fzero%2F1.0%2F)%3C%2Fdc%3Arights%3E%3C%2Frdf%3ADescription%3E%3C%2Frdf%3ARDF%3E%3C%2Fmetadata%3E%3Cmask%20id%3D%22viewboxMask%22%3E%3Crect%20width%3D%22560%22%20height%3D%22560%22%20rx%3D%220%22%20ry%3D%220%22%20x%3D%220%22%20y%3D%220%22%20fill%3D%22%23fff%22%20%2F%3E%3C%2Fmask%3E%3Cg%20mask%3D%22url(%23viewboxMask)%22%3E%3Crect%20fill%3D%22%23ffffff%22%20width%3D%22560%22%20height%3D%22560%22%20x%3D%220%22%20y%3D%220%22%20%2F%3E%3Cg%20transform%3D%22translate(136%20328)%22%3E%3Cpath%20d%3D%22M159.8%20103c-3.2-2.8-6-6.4-9.7-8.1-18-8.5-31.4-21.7-44-36.9-14-16.7-28-34.4-49-43.4-8-3.5-16.3-7.8-24.7%200C22%2024.1%209.6%2033%2012.4%2049.1c2.5%2014%2011%2024.6%2022.6%2033.8%2026.5%2021.1%2058%2026.5%2090%2030.7%2011.8%201.6%2025.3%201.5%2034.8-10.6Z%22%20fill%3D%22%23fff%22%2F%3E%3Cpath%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M104.8%2038.9a85.7%2085.7%200%200%200-24-23.6c-4.2-4.4-9.2-6.3-14-8-2-.8-4-1.5-5.8-2.4-22-10.3-48.1.7-57.4%2023.3a50.7%2050.7%200%200%200%2016.1%2058.2c20.7%2017.7%2045.5%2030%2072.1%2035.7%2022.7%205%2045%207.8%2067.9.5%208.8-2.8%2016-7.1%2017.1-16.5%201.1-8.2-3.5-14.4-10.8-18.7-1.5-.9-2.9-2-4.3-3.2-1.5-1.2-3-2.4-4.8-3.4-19.5-11.2-38.2-23-52-42Zm52%2061.3%203%202.8c-9.5%2012.1-23%2012.2-34.9%2010.6-31.8-4.2-63.4-9.6-90-30.7a55.9%2055.9%200%200%201-22.5-33.8C9.9%2034.8%2019.5%2026%2029%2017.7l3.4-3c8-7.4%2015.7-4%2023.3-.7l1.5.6c19.9%208.6%2033.4%2024.8%2046.6%2040.7L106%2058A131.4%20131.4%200%200%200%20150.1%2095c2.5%201.2%204.6%203.2%206.7%205.3Z%22%20fill%3D%22%23000%22%2F%3E%3C%2Fg%3E%3Cg%20transform%3D%22translate(246%20125)%22%3E%3Cpath%20d%3D%22M45.4%20194.6c-5%20.2-8.7-.4-12-2.9-2.8-2-3.2-4.8-2.6-7.9.5-3.3%203.2-3.8%205.8-3.6%2014.1.7%2028-.5%2041.1-6.4%203.2-1.5%206-.2%207.7%202.6%201.7%203.1%202%206.3-.8%209.4-5%205.8-11.2%209-19%208.8H45.5Z%22%20fill%3D%22%23000%22%2F%3E%3C%2Fg%3E%3Cg%20transform%3D%22translate(-45%20137)%22%3E%3Cpath%20d%3D%22M409.2%2075.7c13.1.3%2025.4%201%2037.7%202.5%203%20.3%204.9%203.3%205%206.6%200%203.4-1.8%205.7-4.8%207-11.1%204.9-22%208.3-33.7.2-6.5-4.4-8.9-8.6-4.2-16.3ZM254.7%2078.4c6.2%203.3%205.2%207%202.1%2010.8-6.5%208-28.2%2010-36.4%203.5-4.7-3.8-7.3-8.6-4.4-14.4%203-6%208.2-5%2013-2.5%208%204%2016.4%203%2025.7%202.6Z%22%20fill%3D%22%23000%22%2F%3E%3C%2Fg%3E%3Cg%20transform%3D%22translate(-45%20137)%22%3E%3C%2Fg%3E%3Cg%20transform%3D%22translate(119%20114)%22%3E%3Cpath%20d%3D%22M57.5%2041.8C51.3%2041.3%2046%2041%2041%2041c-5.7-.2-8.5-3.4-9-8.8-.5-5.3%203-7%207.5-8.5%208.6-3%2017.1-.5%2025.2.7%2015.4%202.1%2031.5-.6%2046.4%206.3%205%202.3%208.3%204.7%206.4%2010.3-1.8%205.2-6.1%205.2-10.6%204.1-16-3.7-32.4.9-49.4-3.3ZM251.8%2032c17.2.9%2033.1-5%2049.3-1.2%204%201%209%20.7%208.8%207%200%206.2-4.7%207.4-9.5%208-19%202.2-38%204-56.9%206.4-5.7.7-11%20.1-12.6-5.6-1.7-5.7%204-7.8%208-10%203.5-2.1%207.8-3.1%2012.9-4.7Z%22%20fill%3D%22%23000%22%2F%3E%3C%2Fg%3E%3C%2Fg%3E%3C%2Fsvg%3E)
Summary
Experience
Sep 2021Present
Senior Medical WriterBioGenix Pharma
San Diego, CAJul 2018Aug 2021
Medical WriterSciMed Communications
San Diego, CAPortfolio & Projects
Mar 2022Sep 2022
Clinical Trial Protocol Development for Rare Disease
Nov 2020May 2021
Patient Education Series: Understanding Type 2 Diabetes
Education
Sep 2016May 2018
University of California, San DiegoMaster of Science in Biomedical Writing
La Jolla, CASkills
Clinical Study Reports (CSRs)Regulatory Submissions (IND, NDA)Manuscript DevelopmentAbstracts & PostersMedical EducationSOPs & GuidelinesData Interpretation & SynthesisLiterature ReviewAMA Style GuideICH GCP GuidelinesTarget Audience AdaptationPeer Review Process